Best practices: Antenatal screening for common genetic conditions other than aneuploidy

Current Opinion in Obstetrics and Gynecology

Volumn 22, Issue 2, 2010, Pages 139-145

  Ram, Kavitha T ^a   Klugman, Susan D ^b  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Carrier screening; Genetic testing; Prenatal counseling; Prenatal diagnosis

Indexed keywords

ANEUPLOIDY; BLOOM SYNDROME; CANAVAN DISEASE; CLINICAL PROTOCOL; CYSTIC FIBROSIS; DYSAUTONOMIA; FANCONI ANEMIA; FRAGILE X SYNDROME; GAUCHER DISEASE; GENE MUTATION; GENETIC DISORDER; GENETIC RISK; GENETIC SCREENING; HEMOGLOBINOPATHY; HETEROZYGOTE DETECTION; HIGH RISK POPULATION; HUMAN; JEW; MEDICAL ETHICS; MEDICAL PRACTICE; MUCOLIPIDOSIS; NIEMANN PICK DISEASE; PRENATAL SCREENING; PRIORITY JOURNAL; REVIEW; SPINAL MUSCULAR ATROPHY; TAY SACHS DISEASE;

FEMALE; GENETIC COUNSELING; GENETIC DISEASES, INBORN; HETEROZYGOTE DETECTION; HUMANS; PATIENT SELECTION; PREGNANCY; PRENATAL DIAGNOSIS;

EID: 77949350904     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/GCO.0b013e3283372379     Document Type: Review

References (41)

1. Wilson JMG, Jungner G. Principles and practice of screening for disease. Geneva, Switzerland: World Health Organization Chronicle; 1968; 473.
2. Andermann A, Blancquaert I, Beauchamp S, Dery V. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ 2008; 86:317-319.
3. Motulsky AG. Frequency of sickling disorder in U.S. blacks. N Engl J Med 1973; 288:31-33.
4. Michlitsch J, Azimi M, Hoppe C, et al. Newborn screening for hemoglobinopathies in California. Pedtr Blood Cancer 2009; 52:486-490.
5. Behrman RE. Cystic fibrosis. In: Nelson Textbook of Pediatrics, 14th edition, Philadelphia: WB Saunders Co. 1992, 1106-1116.
6. Cystic Fibrosis Foundation. Patient registry 2005 annual data report. Bethesda, MD: Cystic Fibrosis Foundation; 2006.
7. Palomaki GE, Haddow JE, Bradley LA, FitzSimmons SC. Updated assessment of cystic fibrosis mutation frequencies in non Hispanic Caucasians. Genet Med 2002; 4:90-94.
8. Grody WW, Cutting GR, Klinger KW, et al. Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. Genet Med 2001; 3:149-154.
9. American College of Obstetrics and Gynecology and American College of Medical Genetics. Preconception and prenatal carrier screening for cystic fibrosis, clinical and laboratory guidelines. 2001. American College of Obstetrics and Gynecology publication. Washington, DC.
10. Southern KW. Cystic fibrosis and formes frustes of CFTR-related disease. Respiration 2007; 74:241-251.
11. Fares F, Badarneh K, Abosaleh M, et al. Carrier frequency of autosomalrecessive disorders in the Ashkenazi Jewish population: should the rationale for mutation choice for screening be reevaluated? Prenat Diagn 2008; 28:236-241.
12. Gross SJ, Pletcher BA, Monaghan KG. Carrier screening in individuals of Ashkenazi Jewish descent. Genet Med 2008; 10:54-56.
13. ACOG Committee Opinion Number 442. Preconception and prenatal carrier screening for genetic diseases in individuals of Eastern European Jewish descent. Obstet Gynecol 2009; 114:950-953.
14. Kaback M, Lim-Steele J, Dabholkar D, et al. Tay-Sachs disease-carrier screening, prenatal diagnosis, and the molecular era. An international perspective, 1970-1993. The International TSD Data Collection Network. JAMA 1993; 270:2307-2315.
15. Monaghan KG, Feldman GL, Palomaki GE, Spector EB. Technical standards and guidelines for reproductive screening in the Ashkenazi Jewish population. Genet Med 2008; 10:57-72.
16. Weinreb NJ, Deegan P, Kacena KA, et al. Life expectancy in Gaucher disease type 1. Am J Hematol 2008; 83:896-900.
17. Azuri J, Elstein D, Lahad A, et al. Asymptomatic Gaucher disease: implications for large scale screening. Genet Test 1998; 2:297-299.
18. Lunn MR, Wang CH. Spinal muscular atrophy. Lancet 2008; 371:2120-2133.
19. Crawford TO, Pardo CA. The neurobiology of childhood spinal muscular atrophy. Neurobiol Dis 1996; 3:97-110.
20. Pearn J. Genetic studies of acute infantile spinal muscular atrophy (SMA type I). An analysis of sex ratios, segregation ratios and sex influence. J Med Genet 1978; 15:414-417.
21. Oskoui M, Levy G, Garland CJ, et al. The changing natural history of spinal muscular atrophy type 1. Neurology 2007; 69:1931-1936.
22. Kroksmark AK, Beckung E, Tulinius M. Muscle strength and motor function in children and adolescents with spinal muscular atrophy II and III. Europ J Paediatr Neurol 2001; 5:191-198.
23. Lefebvre S, Burglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy determining gene. Cell 1995; 80:155-165.
24. Wirth B. An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Hum Mutat 2000; 15:228-237.
25. MacKenzie AE, Jacob P, Surh L, Besner A. Genetic heterogeneity in spinal muscular atrophy: a linkage analysis based assessment. Neurology 1994; 44:919-924.
26. Prior TW. Carrier screening for spinal muscular atrophy. Genet Med 2008; 10:840-842.
27. Committee on Genetics. ACOG Committee Opinion: Spinal Muscular Atrophy. Obstetrics and Gynecology 2009; 113:1194-1196.
28. Hagerman RJ, Hagerman PJ, editors. Fragile X syndrome: diagnosis, treatment and research. 3rd ed. Baltimore: Johns Hopkins University Press. 2002.
29. Warren ST, Sherman SL. The fragile X syndrome. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. Metabolic Basis of Inherited Disease, 8th edition. New York: McGraw Hill; 2001. pp. 1257-1289.
30. Fu YH, Kuhl DP, Pizzuti A, et al. Variation of theCGG repeat at the fratile X site results in genetic instability: resolution of the Sherman paradox. Cell 1991; 67:1047-1058.
31. Verkerk AJ, Pieretti M, Sutcliffe JS, et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 1991; 65:905-914.
32. Nolin SL, Brown WT, Glicksman A, et al. Expansion of the fragile X CGG repeat in females with premutation or intermediate alleles. Am J Hum Genet 2003; 72:454-464.
33. Zestman S, Zwaigenbaum L, Whelan DT, et al. Paternal transmission of fragile X syndrome. Am J Med Genet 2004; 129A:184-189.
34. Sherman SL. Premature ovarian failure in the fragile X syndrome. Am J Med Genet 2000; 97:189-194.
35. Hagerman RJ, Leehey M, Heinrichs W, et al. Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology 2001; 57:127-130.
36. Sofocleous C, Kolialexi A, Mavrou A. Molecular diagnosis of Fragile X syndrome. Expert review of Molecular Diagnositics 2009; 9:23-30.
37. Musci TJ, Caughey AB. Cost-effectiveness analysis of prenatal population based fragile X carrier screening. Am J Obstet Gynecol 2005; 192:1905-1912.
38. Cronister A, Teicher J, Rohlfs EM, et al. Prevalence and instability of fragile X alleles: implications for offering fragile X prenatal diagnosis. Obstet Gynecol 2008; 111:596-601.
39. Fanos JH, Spangner KA, Musci TJ. Attitudes toward prenatal screening and testing for fragile X. Genet Med 2006; 8:129-133.
40. Lander ES, Lindton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature 2001; 409:860-921.
41. Norton ME. Genetic screening and counseling. Curr Opin Obstet Gynecol 2008; 20:157-163.